Results 131 to 140 of about 16,022 (277)

A tutorial on physiologically based pharmacokinetic approaches in lactation research

open access: yesCPT: Pharmacometrics & Systems Pharmacology
In breastfeeding mothers, managing medical conditions presents unique challenges, particularly concerning medication use and breastfeeding practices.
Amita Pansari   +3 more
doaj   +1 more source

Prediction of Monoclonal Antibody Pharmacokinetics in Pediatric Populations Using PBPK Modeling and Simulation

open access: yesPharmaceutics
Background: Accurately determining pediatric dosing is essential prior to initiating clinical trials or administering medications in routine clinical settings. In children, ethical considerations demand careful evaluation of both safety and effectiveness.
Chiara Zunino   +4 more
doaj   +1 more source

Efavirenz and CYP2C9 Genetic Polymorphisms Reduce CYP2C9 Activity in Healthy Participants

open access: yesClinical and Translational Science, Volume 19, Issue 2, February 2026.
ABSTRACT Efavirenz's effects on cytochrome P450 2C9 (CYP2C9) activity have not been formally characterized in vivo. We conducted the first clinical drug–drug interaction (DDI) study to test the effect of chronic efavirenz dosing on CYP2C9 activity, using tolbutamide as a selective probe.
Jason D. Kim   +4 more
wiley   +1 more source

Advanced In Vivo Prediction by Introducing Biphasic Dissolution Data into PBPK Models [PDF]

open access: gold, 2023
Alexander Denninger   +3 more
openalex   +1 more source

In Vivo Efficacy of Zinc Phthalocyanine Nanocarriers IN Photodynamic Therapy of Cancer

open access: yesAdvanced Therapeutics, Volume 9, Issue 1, January 2026.
Zinc phthalocyanines are photosensitizing agents used in photodynamic therapy. Their incorporation into nanosystems enables their encapsulation, targeting, and functionalization, optimizing their therapeutic activity. The results highlight their therapeutic potential, reinforcing their relevance as an innovative strategy in cancer treatment and as a ...
Adrian Lima Roberto   +4 more
wiley   +1 more source

AZD0449, an inhaled JAK1 inhibitor, in healthy participants and patients with mild asthma

open access: yesBritish Journal of Clinical Pharmacology, Volume 92, Issue 1, Page 257-268, January 2026.
Aims Inhaled corticosteroids (ICS) plus bronchodilator are recommended for the treatment of asthma. Targeting the JAK1‐dependent pathway may be an alternative for asthma management in patients with incomplete response to ICS. The aim of this study was to investigate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of AZD0449, a
Anna Lundahl   +11 more
wiley   +1 more source

Home - About - Disclaimer - Privacy